However, single‐agent treatment with CD47‐SIRPα blocking therapeutics in patients is associated with a lack of therapeutic effect at the maximum tolerated dose (MTD) and significant dose‐limiting toxicity (DLT), most notably anaemia and thrombocytopenia.12, 13, 14. This evidence concerns the gene SIRPA and anemia (phenotype).